

Page 10, line 26, change "lease" to --leash--; line 27, change "lease" to --leash--; line 30, change "lease" to --leash--; line 30, change "support-lease" to --support-leash--; line 32, change "lease" to --leash--.

Page 11, line 13, change "trimethloxysilane" to --trimethyloxysilane--; line 16, change "organosilane" to --organosilanes--; line 18, change "lease" to --leash--; line 19, change "include" to --includes--.

Page 12, line 13, change "and" (first instance) to --or--; line 32, change "and" to --or--.

Page 14, line 15, change "is" to --are--.

Page 20, line 17, change "is" to --are--.

Page 22, line 27, change "is" to --are--.

In the Claims:

Please amend the following claims:

1. (Amended) A process for sequentially separating enantiomers from a fluid solution containing said enantiomers comprising the steps of:

(a) treating a fluid containing said enantiomers by means of electrophoresis with a macrocyclic antibiotic to cause said enantiomers to sequentially separate one from another, said macrocyclic antibiotic being selected from the group consisting of ansamacrolides, macrolides, macrocyclic peptides, polyenes and derivatives thereof, said macrocyclic antibiotic interacting with said enantiomers to cause sequential separation by means of more

A2
cont. than one of the following mechanisms: complexation, charge-charge interaction, hydrogen bonding, inclusion in a hydrophobic pocket, dipole stacking, or steric interaction, and

(b) recovering the sequentially separated enantiomers as individual enantiomers.

A3
2. (Amended) The process of claim 1 wherein said [macrocyclic antibiotic is selected from the group consisting of: ansamacrolides, macrolides, macrocyclic peptides, glycopeptides, polyenes and derivatives thereof] macrocyclic peptide is a glycopeptide.

09187369-110699
3
2. (Amended) The process of claim [2] 1 wherein [said process is membrane separation, electrophoresis or chromatography and] said macrocyclic antibiotic is affixed to a support and said treating step comprises contacting said fluid with said macrocyclic antibiotic attached to said support.

A4
7'
2. (Amended) The process of claim [2] 1 wherein [said process is electrophoresis or chromatography and said treating step comprises adding] said macrocyclic antibiotic [as] is a mobile phase additive.

Please cancel claims 2, 4, 8, 9 and 10.

Please add the following new claims:

~~15~~⁸ 15. The process of claim 1 wherein said ansamacrolides are selected from the group consisting of naphthoquinoid ansamacrolides and benzoquinoid ansamacrolides.

~~16~~⁹ 16. The process of claim ~~15~~⁸ wherein said naphthoquinoid ansamacrolides are selected from the group consisting of streptovaricins, rifamycins, tolypomycins, halomicins, and naphthomycins.

~~17~~¹⁰ 17. The process of claim ~~15~~⁸ wherein said benzoquinoid ansamacrolides are selected from the group consisting of geldanamycin and maytansinoids.

~~18~~¹¹ 18. The process of claim 1 wherein said macrolides are selected from the group consisting of chalcomycin, methymycin, neomethymycin, erythromycin, megalomycin, picromycin, narbomycin, oleandomycin, triacetyloleandomycin, carbomycin, spiramycin, tylosin and derivatives thereof.

~~19~~¹² 19. The process of claim 1 wherein said macrocyclic peptides are selected from the group consisting of sporidesmolides, capreomycin, ristomycin, cyclosporins, tyrocidine, triostins, gramicidins, tyrocidines, polymyxins, bacitracins, octapeptins, actinomycins, etamycins, vernamycins, enniatins, valinomycin, thiostrepton, teichomycin, avoparcin,

actaplanins, vancomycin and derivatives thereof.

¹³
~~21~~ 20. The process of claim 1 wherein said polyenes are selected from the group consisting of amphotericin, candicidin, candidin, dermostatin, fungichromin, nystatin and derivatives thereof.

⁴
~~21~~ 21. The process of claim ³~~8~~ wherein said support is selected from the group consisting of silica gel, alumina, polystyrenes, polyurethanes, polyvinyl alcohols, polyamides, agarose, cellulose, dextran and linear and branched amylose.

⁵
~~21~~ 22. The process of claim ³~~8~~ wherein said macrocyclic antibiotic is chemically bonded to said support.

⁶
~~21~~ 23. The process of claim ³~~8~~ wherein said macrocyclic antibiotic is coated on said support.

¹⁴
~~25~~ 24. A process for sequentially separating enantiomers from a fluid solution containing said enantiomers comprising the steps of:

(a) treating a fluid containing said enantiomers by means of electrophoresis with a macrocyclic antibiotic to cause said enantiomers to separate one from another, said macrocyclic antibiotic being selected from the group consisting of aplasmomycin, boromycin, enterobactin, bebeerine and derivatives

thereof, said macrocyclic antibiotic interacting with said enantiomers to cause sequential separation by means of more than one of the following mechanisms: complexation, charge-charge interaction, hydrogen bonding, inclusion in a hydrophobic pocket, dipole stacking, or steric interaction; and

(b) recovering the sequentially separated enantiomers as individual enantiomers.

AS
Court
09187369-110608
24¹⁶ 28. The process of claim 24¹⁴ wherein said macrocyclic antibiotic is affixed to a support and said treating step comprises contacting said fluid with said macrocyclic antibiotic attached to said support.

27¹⁵ 28. The process of claim 24¹⁴ wherein said macrocyclic antibiotic is a mobile phase additive.

28¹⁷ 27. The process of claim 25¹⁶ wherein said support is selected from the group consisting of silica gel, alumina, polystyrenes, polyurethanes, polyvinyl alcohols, polyamides, agarose, cellulose, dextran and linear and branched amylose.

27¹⁸ 28. The process of claim 25¹⁶ wherein said macrocyclic antibiotic is chemically bonded to said support.

28¹⁹ 29. The process of claim 25¹⁶ wherein said macrocyclic antibiotic is coated on said support.